Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methandriol is a synthetic anabolic-androgenic steroid (AAS) belonging to the class of androgens and derivatives. It is a 3-hydroxylated C19 steroid hormone known to favor the development of masculine characteristics and has profound effects on scalp and body hair in humans. Methandriol acts as an agonist of the androgen receptor, mimicking the effects of endogenous testosterone but with modifications that enhance its anabolic properties. It has been used experimentally but is not approved for medical use in major regulatory jurisdictions[1][2]. Methandriol is considered an illicit or controlled substance in many regions due to its potential for misuse as a performance-enhancing drug[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methandriol.